XPAR
MAAT
Market cap92mUSD
May 15, Last price
5.06EUR
1D
-0.78%
1Q
-30.43%
IPO
-62.63%
Name
Maat Pharma SA
Chart & Performance
P/E
—
P/S
36.60
EPS
—
Div Yield, %
—
Shrs. gr., 5y
61.57%
Rev. gr., 5y
20.09%
Revenues
2m
+55.80%
Net income
-20m
L+42.16%
CFO
-19m
L+48.12%
Profile
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 2,228 55.80% | 1,430 47.12% | |||||
Cost of revenue | 23,871 | 16,627 | |||||
Unusual Expense (Income) | |||||||
NOPBT | (21,643) | (15,197) | |||||
NOPBT Margin | |||||||
Operating Taxes | 157 | ||||||
Tax Rate | |||||||
NOPAT | (21,643) | (15,354) | |||||
Net income | (19,717) 42.16% | (13,870) 51.75% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 12,513 | (35) | |||||
BB yield | -15.77% | 0.04% | |||||
| Debt | |||||||
Debt current | 2,223 | 2,987 | |||||
Long-term debt | 15,815 | 9,020 | |||||
Deferred revenue | |||||||
Other long-term liabilities | 323 | 323 | |||||
Net debt | (6,276) | (23,740) | |||||
| Cash flow | |||||||
Cash from operating activities | (18,670) | (12,605) | |||||
CAPEX | (1,093) | (662) | |||||
Cash from investing activities | (440) | (815) | |||||
Cash from financing activities | 8,141 | 5,364 | |||||
FCF | (29,266) | (15,280) | |||||
| Balance | |||||||
Cash | 24,314 | 35,311 | |||||
Long term investments | 436 | ||||||
Excess cash | 24,203 | 35,676 | |||||
Stockholders' equity | (16,695) | (11,513) | |||||
Invested Capital | 50,327 | 49,962 | |||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 11,365 | 9,892 | |||||
Price | 6.98 -12.75% | 8.00 -40.07% | |||||
Market cap | 79,328 0.24% | 79,134 144.29% | |||||
EV | 73,052 | 55,394 | |||||
EBITDA | (20,772) | (14,768) | |||||
EV/EBITDA | |||||||
Interest | 402 | 185 | |||||
Interest/NOPBT | |||||||